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Curettageof cervical involvement is important to establish a rational treatment for
endometrial cancer patients. We investigated the value of preoperative endocervical curettage (ECC) in
predicting cervical involvement.
Methods. Preoperative ECC of 290 patients with clinical stage I epithelial endometrial cancer was
compared with histopathology of the uterus.
Results. Amongst all ECCs, 245 (84.5%) were negative and 45 (15.5%) were positive for endometrial cancer.
In the uterine specimen, cervical involvement was found in 20% (58/290). PPV and NPV of ECC were 86.7%
and 92.2%. False negative and false positive ECC occurred in 6.6% and 2.1%. Of all patients with positive ECC,
46.7% had FIGO stage II disease and 46.7% had extra uterine tumor spread (FIGO III, IV).
Conclusion. ECC is an acceptable diagnostic tool to predict the presence or absence of cervical involvement
in early stage endometrial cancer patients.
© 2008 Elsevier Inc. All rights reserved.Introduction
Endometrial cancer is themost common gynecological malignancy
in developed countries and 90% of the patients are postmenopausal
[1]. In most women endometrial cancer is detected at an early stage as
postmenopausal vaginal bleeding is an early presenting symptom.
Tumour stage, grade, histological type, depth of myometrial invasion
[2–7], lymph vascular space invasion (LVSI) [8] and age [4,9] are
known prognostic factors in endometrial cancer.
In 1988, the International Federation of Gynecology and Obstetrics
(FIGO) redeﬁned stage of disease on the basis of surgical pathological
criteria. The main intent of the staging system was to establish a
rational treatment program for each individual patient. Extension of
endometrial carcinoma to the cervix, which was ﬁrst described by
Heyman in 1941, occurs in 10 to 15% of all cases of endometrial cancer.
Since cervical invasion of endometrial cancer is recognized to increase
the risk of pelvic lymph node metastases [10,11], a more extended
surgical procedure is recommended including pelvic and para aortic
lymph node dissection, performed by a gynecological oncologist in a
specialized centre [3,10,12]. When cervical involvement is found after
the operation and no lymphadenectomy has been performed, patients
are treated with adjuvant radiotherapy. Morbidity of adjuvant radio-
therapy is substantial. Especially mild, mainly gastrointestinal, side
effect are common, of which 50% are transient[13].urits).
l rights reserved.Endocervical curettage (ECC) has been commonly used to assess
cervical involvement, but the accuracy of this procedure remains
controversial [7,10,11,14–19]. The aim of this study is to investigate the
value of ECC as a diagnostic procedure in the preoperative staging of




Since 1978, clinicopathological and follow-up data of all patients
referred to the Department of Gynecological Oncology of the
University Medical Centre Groningen are prospectively collected
during treatment and follow-up and stored in a computerized
registration database, which is managed in accordance with the
hospital regulations.
For the current study, all consecutive endometrial cancer patients
(n=771) treated between January 1978 and January 2006 were
selected. Excluded were patients with a non-epithelial endometrial
cancer (n=166). Secondly, patients with macroscopically cervical
involvement (i.e. clinical stage IIB) were excluded (n=47). Finally,
patients with extended disease who did not undergo surgical
treatment and patients who received preoperative radiotherapy
were excluded (n=21). Of the remaining patients, preoperative
diagnostic procedures were not performed in 165 patients and in
another 74 patients the histopathological reports could not be
Table 1
Clinicopathological characteristics of 290 clinical early stage epithelial endometrial
carcinoma patients
Overall
Mean age in years (n=290) 63.4 (11.2)
Differentiation grade (n=275)a
I (well differentiated) 139 (50.5%)
II (moderately differentiated) 88 (32.0%)
III (poorly differentiated) 46 (16.7%)
IV (undifferentiated) 2 (0.7%)
Histological subtype (n=290)
Adenocarcinoma 248 (85.5%)
Adenosquamous carcinoma 11 (3.8%)
Clearcell carcinoma 14 (4.8%)
Papillary serous carcinoma 11 (3.8%)
Undifferentiated 3 (1.0%)
Other 3 (1.0%)
Depth of myometrial invasion (n=288)b
Endometrium only 31 (10.8%)
b1/2 in myometrium 153 (53.1%)




Year of diagnosis (n=290)
First decade (1978–1987) 58 (20.0%)
Second decade (1988–1996) 110 (37.9%)
Third decade (1997–2006) 122 (42.1%)
Type of operation (n=290)
Simple hysterectomy 173 (59.7%)




Missing values in respectively 15 (5.1%)a, 2 (0.7%)b ,19 (6.5%)c and 2 (0.7%)d patients.
Table 2







Mean age in years (n=58) 63.9 (11.1)
Age≤63 years 1 n.i.
Age N 64 years 0.9 (0.5–1.6)
Differentiation grade (n=51)a
Well differentiated 19 (37.3%) 1 n.i.
Moderately differentiated 19 (37.3%) 1.7 (0.9–3.5)
Poorly-undifferentiated 13 (25.5%) 2.3 (1.1–5.2)⁎
Histological subtype (n=58)
Adenocarcinoma,-squamous 50 (86.2%) 1 n.i.
Clearcell/serous/undiff/other 8 (13.8%) 1.5 (0.6–3.4)
Depth of myometrial invasion (n=57)b
Endometrium only 2 (3.5%) 1 1
b1/2 in myometrium 21 (36.8%) 2.3 (0.5–10.4) 2.3 (0.5–10.4)
≥1/2 in myometrium 34 (59.6%) 7.0 (1.6–31.3)⁎ 7.0 (1.6–31.3)
LVSI (n=53)c
Negative 33 (62.3%) 1 n.i
Positive 20 (37.7%) 2.6 (1.4–5.0)⁎
Year of diagnosis (n=58)
First decade (1978–1987) 14 (24.1%) 1 n.i.
Second decade (1988–1996) 20 (34.5%) 0.70 (0.3–1.5)
Third decade (1997–2006) 24 (41.4%) 0.77 (0.4–1.6)
Missing values in respectively 7(12.1%)a, 1(1.7%)b and 5(8.6%)c patients.
⁎pb0.05; n.i.=not included.
522 C.B.M. Bijen et al. / Gynecologic Oncology 112 (2009) 521–525retrieved. In total, preoperative assessment of cervical involvement
was carried out by endocervical curettage (ECC) or endocervical biopsy
(ECB) in 290 and 8 patients, respectively. There were no statistically
signiﬁcant differences on the main characteristics (tumour stage,
differentiation grade, histological sub type, depth of myometrial
invasion, age) between the women with an ECC performed (n=290)
and the women without an ECC performed (n=165). Due to small
sample size the ECB group was not considered in further analyses,
resulting in 290 patients with clinical stage I disease.
After preoperative clinical staging, patients underwent primary
surgical therapy within four to six weeks according to protocol [20],
which is total abdominal hysterectomy and bilateral salpingo oophor-
ectomy in case of a clinical stage I disease and total abdominal hyste-
rectomy and bilateral salpingo oophorectomy, pelvic and para aortic
lymphadenectomy in case of a clinical stage IIA (positive ECC) disease.
IRB approval
For the present study, all relevant data were retrieved from our
computerized database into a separate, anonymous password pro-
tected database. Patients' identity was protected by study speciﬁc,
unique patient numbers, which codes were only known to two
dedicated data managers. In case of uncertainties with respect to
clinicopathological and follow-up data, the larger databases could
only be checked through the data managers, thereby ascertaining the
protection of the patients' identity. Due to these procedures according
to Dutch law, no further patient or International Review Board (IRB)
approval was needed.Methods
In all patients, the diagnosis of endometrial cancer was histopatho-
logically established preoperatively by micro curettage (pipelle) or
fractionated curettage. Subsequently, endocervical tissue was obtained
by ECC. Histopathological results of the ECC slideswere divided into two
different groups, namely endometrial cancer in the ECC (i.e. positive)
and no endometrial cancer in the ECC (i.e. negative). These criteria were
based on the leadingwell known atlas of gynecologic surgical pathology
[21] The criterion for preoperative diagnosis of a positive ECC was as
follows: endocervical tissue present and tumour in relation with
cervical tissue. Criteria for preoperative diagnosis of a negative ECC
were as follows: 1) endocervical tissue without cancer; 2) obtained
tissue was insufﬁcient to establish a diagnosis; 3) loose tumour
fragments without relation with endocervical tissue. Our expert
gynecological pathologist (H.H.) judged the majority (∼85%) of all slides
during the initial presentation. Misclassiﬁed slides and slides allocated
to the separate group were revised, without prior knowledge of the
deﬁnitive outcome. The initially interpreted slides and revised slides by
H.H. were used for further analysis. Of the original false negative, false
positive and separate group slides, the review report differed from the
initial diagnosis in 5% (1/20), 57.1% (8/14) and 0% (0/34), respectively. In
total, about 23% (68/290) of the slides were reviewed by H.H of which
3.1% (9/290) differed from the original report.
Surgical pathological information was gathered from the pathol-
ogy reports, which included histological tumour type, grade, FIGO
stage, myometrial invasion and tumour features such as lymph
vascular space involvement. Cervical involvement in the uterine
specimenwas deﬁned as endocervical glandular involvement only (i.e.
FIGO stage IIA) or cervical stromal invasion (i.e. FIGO stage IIB).
Statistical analysis
Preoperative histopathological results of ECC were compared with
deﬁnitive histopathological results of cervical involvement obtained
Table 3
Predictive values of ECC for cervical involvement found in ﬁnal uterine specimen
(n=290)




Positive 39 6 45




Histopathological features of FIGO stage I (n=192) and FIGO stage≥ II (n=98)
(FIGO I) (FIGO ≥ II) Odds ratio
Univariate Multivariate
ECC (n=290)
Negative 189 (77.1%) 56 (22.9%) 1 1





Well differentiated 108 (77.7%) 31 (22.3%) 1 1
Moderately
differentiated
56 (63.6%) 32 (36.4%) 2.0 (1.1–3.6) 1.6 (0.8–3.2)
Poorly-
undifferentiated




177 (68.3%) 82 (31.7%) 1 n.i.
Clearcell/serous/
undiff/other
15 (48.4%) 16 (51.6%) 2.3 (1.1–4.9)⁎
Depth of invasion (n=288)b
Endometrium only 26 (83.9%) 5 (16.1%) 1 1
b 1/2 in myometrium 117 (76.5%) 36 (23.5%) 1.6 (0.6–4.5) 2.6 (0.6–11.6)
≥ 1/2 in myometrium 48 (46.2%) 56 (53.8%) 6.1 (2.2–17.0)⁎ 7.3 (1.6–33.4)⁎
LVSI (n=271)c
Negative 153 (72.9%) 57 (27.1%) 1 n.i
Positive 30 (49.2%) 31 (50.8%) 2.8 (1.5–5.0)⁎
Missing values in respectively 15 (5.1%)a, 2 (0.7%)b and 19 (6.5%)c patients.
⁎pb0.05.
⁎⁎pb0.001 n.i.=not included.
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features of the patients were described in total and for the patient
group in which cervical involvement was found (Tables 1 and 2).
Univariate logistic regression analyses were performed with cervical
involvement as dependent variable and the histopathological char-
acteristics as described in Table 2 as independent variables. Odds
ratios (OR's) and 95% conﬁdence intervals (95%-CI's) were calculated.
Multivariate logistic analysis was performed by using a backward step
model with cervical involvement as dependent variable and the
statistically signiﬁcant related variables, as assessed in the univariate
logistic regression analysis, as independent variables. Variables were
excluded from the model if p≥0.05.
With cervical involvement in the hysterectomy specimen as gold
standard, positive predictive value (PPV), negative predictive value
(NPV) and misclassiﬁcation (1-accuracy) were calculated for the ECC
procedure. Logistic regression analyses were performed using age,
differentiation grade and histological subtype as potential predictors
for misclassiﬁcation.
In Table 4, histopathological features of early and advanced stage
patients were characterized. Logistic regression analyses were
performed with advanced stage disease as dependent variable and
known prognostic factors (cervical involvement, differentiation grade,
histological subtype, depth of myometrial invasion and LVSI) as
independent variables. All statistical analyses were performed using




Clinicopathological characteristics of 290 clinical early stage
epithelial endometrial carcinoma patients are given in Table 1. The
majority of the patients had well to moderately differentiated
carcinomas of the uterus (82.5%). About 11% of the patients had no
myometrial invasion, but endometrial carcinoma limited to the
endometrium only (FIGO stage IA). LVSI was present in 22.5% of all
patients. The contribution of included patients over decades was
equally distributed for the last two decades (about 40% per decade).
The lowest number of patients was included in the ﬁrst decade (20%).
Nearly 60% of all patients did undergo a simple hysterectomy (without
lymphadenectomy). A substantial part of the patients (56.3%) received
radiotherapy after surgery. The clinicopathological characteristics of
the patients were related to the presence of cervical involvement in
the uterine specimen (Table 2). On multivariate analysis, only depth of
invasion≥of the myometrium (OR: 7.0; 95%-CI: 1.6–31.3) was
statistically signiﬁcantly associated with presence of cervical
involvement.
Diagnostic value of ECC in predicting cervical involvement in the
uterine specimen
Cervical involvement in the ﬁnal uterine specimenwas found in 58
(20%) of 290 patients (Table 3). Among all ECC procedures, 245 (84.5%)were negative and 45 (15.5%) were positive for cervical involvement.
The PPV and NPV of ECC were 86.7% and 92.2%, respectively.
Misclassiﬁcation (1-accuracy) occurred in 8.6% (25/290) samples,
consisting of 6.6% (19/290) false negative samples and 2.1% (6/290)
false positive samples. As a potential predictor of misclassiﬁcation,
ageN63 years (OR: 4.0; 95%-CI: 1.3–12.4) was independently related to
the presence of false negative samples (data not shown).
Relation between ECC and FIGO stage
Based on the ﬁnal FIGO stage, 66.2% (192/290) of all included
patients had early stage (FIGO stage I) endometrial cancer and 33.8%
(98/290) had FIGO stage≥ II disease (Table 4). Of all patients with
negative ECC samples, 77.1% (189/245) were classiﬁed as FIGO stage I
and 22.9% (56/245) as FIGO≥ II stage. Of all positive ECC samples, 6.7%
(3/45) were classiﬁed as FIGO stage I disease and 93.3% as FIGO
stage≥ II ,of which 46.7% (21/45) with FIGO stage II disease and 46.7%
(21/45) with extra uterine tumour spread (i.e. FIGO III, IV). On
univariate analysis, a signiﬁcant effect of a positive ECC (OR: 47.3; 95%-
CI: 14.1–158.2), a poorly or undifferentiated grade (OR: 4.5; 95%-CI:
2.2–9.0), a non-endometrioid tumour type (OR: 2.3; 95%-CI: 1.1–
4.9),≥1/2 myometrial invasion (OR: 6.1; 95%-CI: 2.2–17.0) and a
positive LVSI (OR: 2.8; 95%-CI: 1.5–5.0) was found for the presence of
FIGO stage≥ II disease. On multivariate analysis, a positive ECC result
(OR: 41.0; 95%-CI: 11.4–146.8), poorly or undifferentiated tumour cells
(OR: 3.2; 95%-CI: 1.4–7.4) and depth of invasion≥1/2 of myometrium
(OR: 7.3; 95%-CI: 1.6–33.4) were independently associated with
FIGO≥ II stage disease. If we correlated ECC with extra uterine spread
(i.e. FIGO III, IV) the effect remained signiﬁcant (OR: 2.77; 95%-CI: 1.2–
6.3) on multivariate analysis.
Discussion
This is a large study analyzing the role of ECC as a preoperative
staging procedure, in predicting cervical involvement in clinical early
524 C.B.M. Bijen et al. / Gynecologic Oncology 112 (2009) 521–525stage endometrial cancer patients. In these patients, ECC has a PPV of
86.7% and a NPV of 92.2% for cervical involvement in the uterine
specimen. Misclassiﬁcation (i.e. FN and FP samples) occurred in 8.6% of
all cases and false negative samples were only related to age. As can be
seen in Table 1, our patient group is representative for clinical early
stage endometrial cancer patients despite the high amount of missing
patient data.
A broad scope of diagnostic tools is used preoperatively to predict
the presence and extent of uterine disease in endometrial cancer
patients. Numerous studies reported the value of other preoperative
staging procedures in diagnosing cervical involvement, such as
cervical cytology [7,10,12,22], CT scan [23], transvaginal ultrasono-
graphy [12,23] and MRI [23,24]. Cervical cytology, CT and transvaginal
ultrasonography showed poor results and are not suitable for
detecting cervical involvement [7,10,12,22,23]. MR imaging is the
only modality that has been shown to accurately (Q-value 0.92; 95%
CI: 0.87–0.95) depict cervical invasion [24] but due to its high costs
and time consuming factor is not recommended as a routine
procedure in the Dutch guidelines.
In this series, 2.1% of all cases were false positive. The reason for the
amount of changed FP cases after reviewing by H.H. was due to a
wrong interpretation by other pathologists (referral patients, not
revised by H.H) of the ECC samples with free ﬂoating tumour
fragments without cervical tissue (i.e. separate group). These samples
were interpreted as being positive, but according to our study protocol
considered as being negative. Several hypotheses are argued to
explain the occurrence of false positive ECC results. In our study, in
three cases the curetting might have had a therapeutic value by
removing all tumour from the endocervix. In one case a tumour
protruded from the endometrial cavity into the endocervix. From the
pathological report it can be concluded that in the other two cases the
tumour arose in the lower segment of the uterus. Oppositely, during
pathological examination tumour might be missed in a particular
section slide, because of limited number of section slides.
In addition, 6.6% of all cases were false negative. This can be due to
an inadequate technique of curetting or the curette did not reach the
upper segment of the endocervical canal. The latter explanation
occurred in 8 patients, in which a tumour in the upper segment of the
endocervical canal was found in the uterine specimen. As a result,
areas of cervical tumour involvement might escape histological
identiﬁcation. In 8 false negative samples, massive tumour growth
of the cervical canal was found. Therefore, besides loose tumour
fragments, no pre-existent cervical tissue was seen in the ECC.
Actually, these cases might have been missed during speculoscopy.
Furthermore, it has been suggested in some reports that involvement
of the cervical stroma by extension of the tumour can occur under
intact endocervical mucosa, which could explain 3 false negative
samples in our study [25,26]. Moreover, due to curetting, endometrial
tumour cells can be implanted in the endocervical glandular tissue
called cervical implantation metastasis [27]. Another phenomenon
called atypical reactive proliferation involving the endocervical sur-
face is commonly seen in associationwith endometrial cancer and has
the potential to be misinterpreted as endocervical involvement by
tumour in the uterine specimen. Scott and colleagues hypothesized
that the proliferation is most likely a reactive response to recent
curettage [28]. According to this theory, the true number of false
negative samples might be smaller. Overall, in our study only a
signiﬁcant relation was found between false negative samples and
older age (N63 years) (OR: 4.0; 1.3–12.4). Misclassiﬁcation was not
related to differentiation grade and histological subtype. We hypothe-
sized that atrophy of the cervical canal in older postmenopausal
women (i.e.N63 years) might hamper endocervical curetting.
Negative and positive predictive values of the ECC procedure
varied between (87.5%–98.3%) and (15.1%–62.5%) in previous studies
[7,10,12,23,25]. These differences can partly be explained by hetero-
geneity in patient selection and differences in assessment of thecurettage. The strict criteria for selecting patients and the systematic
way of classifying the ECC samples are the strength of our study;
only clinical early stage patients were included. Hence, the
prevalence of cervical involvement in our patient population is
much lower, which exert inﬂuence on the predictive value.
Importantly, we excluded clinically stage IIB patients, as cervical
involvement has already been observed macroscopically during
speculoscopy. In general, ECC has no value in clinical advanced
staged patients. Furthermore, solely speculoscopy to exclude cervical
involvement appears to be insufﬁcient as all included patients did
have a macroscopically normal aspect of the cervix. Secondly, one
gynecopathologist (HH) (re)viewed all slides and was able to
accurately discriminate between positive and negative ECC samples.
Free ﬂoating tumour fragments in the ECC sample were considered
as contamination of tumour tissue from the corpus. These tumour
fragments of the corpus were dragged along the endocervical canal
during curettage or hysteroscopy. Therefore, without co-existing
endocervical tissue this histological result was interpreted as being a
negative ECC [21].
Even though predicting advanced stage disease is not the goal of
ECC, it strikes that in nearly 95% of all positive ECC samples, the
patients had FIGO stage≥ II (Table 4). Consequently, these patients
need amore extended hysterectomy by a gynecological oncologist in a
specialized centre. Despite the high negative predictive value of ECC
(92.2%), only 77.1% of all patients with a negative ECC sample truly did
have FIGO stage I. Amongst the patients with extra uterine tumour
spread (i.e. FIGO stage III or IV), 57.1% (36/63) did not have cervical
involvement in the uterine specimen.
According to Table 4, a positive ECC sample is strongly related to
the presence of FIGO stage≥ II disease. Other important factors related
to FIGO stage≥ II disease were poorly or undifferentiated grade and
depth of invasion≥1/2 of the myometrium. However, these para-
meters can only be assessed accurately postoperative. The risk of FIGO
stage≥ II disease in case of a positive ECC sample is substantial and
might be guidance for the choice of surgical treatment and hence the
centre of treatment.
The main objective is to get the best treatment results with the
least morbidity for each patient. In patients with cervical invasion of
endometrial cancer (i.e. clinical FIGO stage II), a more extended
surgical procedure is recommended including lymphadenectomy,
performed by a gynecological oncologist in a specialized centre
[3,10,12]. As becomes clear from out data, ECC plays an important role
in discriminating patients with clinical stage I or clinical stage IIA
disease and therefore establishing a rational surgical treatment
program for each patient, being either a simple or radical hyster-
ectomy. The main intent of a preoperative ECC is to prevent surgical
“over treatment” or “under treatment”. The chance of “over
treatment” (i.e. lymphadenectomy in case of false positive ECC
samples) and “under treatment” (i.e. no lymphadenectomy in case
of false negative ECC) is low (2.1% and 6.6%).
In conclusion ECC is an acceptable diagnostic tool to predict the
presence or absence of cervical involvement in early stage endome-
trial cancer, allowing selection of patients for either a simple
hysterectomy or a more extended hysterectomy with lymphadenect-
omy, performed by a gynecological oncologist in a specialized centre.
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